Targeted Therapies in Cancer: To Be or Not to Be, Selective

Biomedicines

Justin Taylor¹  Maurizio Affer¹  Deborah Soong¹  Skye Montoya¹  Nina Nguyen¹  Sailasya P. Munamarty¹ 

[1] Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1501 NW 10th Avenue, Miami, FL 33136, USA;

关键词: cancer;    targeted therapies;    resistance mechanisms;    receptor tyrosine kinases;    single kinase inhibitors;    multikinase inhibitors;   

DOI  :  10.3390/biomedicines9111591

来源: DOAJ

【 摘 要 】

Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefore the pathways they activate, cancers can be slowed or completely eradicated, leading to partial or complete remissions for many cancer types. Unfortunately, for many patients, resistance to targeted therapies, such as kinase inhibitors, ultimately develops and can necessitate multiple lines of treatment. Drug resistance can either be de novo or acquired after months or years of drug exposure. Since resistance can be due to several unique mechanisms, there is no one-size-fits-all solution to this problem. However, combinations that target complimentary pathways or potential escape mechanisms appear to be more effective than sequential therapy. Combinations of single kinase inhibitors or alternately multikinase inhibitor drugs could be used to achieve this goal. Understanding how to efficiently target cancer cells and overcome resistance to prior lines of therapy became imperative to the success of cancer treatment. Due to the complexity of cancer, effective treatment options in the future will likely require mixing and matching these approaches in different cancer types and different disease stages.

【 授权许可】

Unknown